Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.53 |
| ▸ | SRC | P12931 | 4/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6592222 | 0.85 | KDM1A (0.56) | EGFRELANEPDPK1KDM1AIRAK1 | |
| SCHEMBL10296328 | 0.85 | KDM1A (0.56) | EGFRELANEPDPK1KDM1AIRAK1 | |
| SCHEMBL3904580 | 0.84 | SRC (0.78) | SRCTGFBR1MET | |
| SCHEMBL3894196 | 0.83 | SRC (0.63) | SRCTGFBR1MET | |
| SCHEMBL371659 | 0.83 | KDM1A (0.52) | EGFRELANEPDPK1KDM1AIRAK1 | |
| SCHEMBL18676689 | 0.83 | KDM1A (0.52) | EGFRELANEPDPK1KDM1AIRAK1 | |
| SCHEMBL30465578 | 0.83 | KDM1A (0.52) | EGFRELANEPDPK1KDM1AIRAK1 | |
| SCHEMBL10947690 | 0.81 | ELANE (0.52) | EGFRELANEPDPK1KDM1AIRAK1 | |
| SCHEMBL13271522 | 0.81 | KDM1A (0.53) | EGFRELANEPDPK1KDM1AIRAK1 | |
| SCHEMBL21884844 | 0.81 | KDM1A (0.53) | EGFRELANEPDPK1KDM1AIRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2247584-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009093049-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | MET, ROS1, ABL1 | EGFR 11/4885SRC 35/4885TGFBR1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.